Status:
COMPLETED
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hyperten...
Eligibility Criteria
Inclusion
- Male and female patients \>=18 years of age with Stage I or II hypertension defined as:
- a mean seated cuff diastolic blood pressure \>=95 and \<=119 mmHg Main
Exclusion
- Pregnant
- breast-feeding
- unwilling to use birth control during the study
- secondary hypertension
- SBP\>=180 mmHg
- DBP\>=120 mmHg
- severe renal dysfunction
- hepatic insufficiency
- stroke within the last 6 months
- myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months
- unstable or uncontrolled diabetes
- history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1354 Patients enrolled
Trial Details
Trial ID
NCT00281593
Start Date
April 1 2006
Last Update
December 28 2017
Active Locations (119)
Enter a location and click search to find clinical trials sorted by distance.
1
1236.1.511 Boehringer Ingelheim Investigational Site
Glendale, Arizona, United States
2
1236.1.574 Boehringer Ingelheim Investigational Site
Tempe, Arizona, United States
3
1236.1.501 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
4
1236.1.557 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States